Dec 21, 2015
Washington Healthcare Update
Congress raced to exit for the holidays and passed a $1.5 trillion omnibus spending bill and $680 billion tax-extenders package on Friday. The omnibus
funds the government through September 2016. President Obama signed the Legislation on Friday. In that package, the medical device tax was suspended for
two years, as was the health insurance tax. The Cadillac tax implementation was also delayed. Both bodies went on to pass legislation concerning meaningful
use and other Medicare changes.
Healthcare.gov signed up 6 million people for coverage beginning Jan.1.
The House convenes on Jan. 5. Majority Leader Kevin McCarthy (R-Calif.) said the House will vote next month on a reconciliation measure that would repeal
key portions of the Affordable Care Act.
The State of the Union is scheduled for Jan. 12.
Because of the congressional recess and holidays, the next update will be Monday, January 11, unless there is breaking healthcare news.
House of Representatives
3. State Activities
4. Regulations Open for Comment
Energy and Commerce Committee Members Ask GAO to Assess FDA’s Review of NBCDs
House Energy and Commerce Committee members wrote a
letter asking the Government
Accountability Office (GAO) to conduct a study to assess the Food and Drug Administration’s (FDA) regulatory pathway for reviewing generic non-biologic
complex drugs (NBCDs). The lawmakers note that non-biologic complex drugs are being approved through the same regulatory pathway as small molecule generic
drugs. They ask GAO to evaluate whether generic NBCDs that are not fully characterized present unique challenges in meeting generic-drug approval standards
that are different from those presented by small-molecule generic drugs.
For the purposes of the study, the lawmakers stated that an NBCD is not fully characterized NBCD if: 1) the active ingredient has molecular diversity; 2)
scientific analytic methodologies are unable to fully identify the molecular structures and physiochemical properties of the active ingredient; and 3) the
nature of the active ingredient is not understood sufficiently to identify all the molecular components that produce the therapeutic effect of the drug and
the mechanisms of action that produce such effect. They also note that the study they are requesting is based on the Generic Complex Drugs Safety and Effectiveness Act, a bill introduced by Rep.
Michael Burgess (R-TX), and that it includes additional questions that should also be addressed.
Oversight Republicans Investigating Generic Backlog
House Oversight Committee Republicans wrote a letter to the U.S. Food
and Drug Administration (FDA) asking for documents about its review of Abbreviated New Drug Applications (ANDA). The letter said there are questions about
the competence of FDA’s review process of generic drug applications due to recent price increases of off-patent drugs with no competitors. FDA oversight of
priority review vouchers is also in question. According to the letter, the vouchers have increased in resale value from $67.5 million to $375 million in
the past year.
Turing Pharmaceuticals CEO Martin Shkreli has recently come under allegations that he bought a $3 million majority stake in KaloBios, which makes a drug
that has yet to be approved in the U.S., to get a priority review voucher and sell it. The members want to know how safeguards work in the priority review
voucher program because some scenarios raise questions about companies that apply for vouchers only to capitalize on the resale market.
House Lawmakers Ask CMS to Change Clinical Diagnostic Laboratory Payment Proposed Rule
On Dec. 17, House lawmakers joined a group a senators in asking the Centers for Medicare and Medicaid Services (CMS) to make changes to the Medicare
Clinical Diagnostic Laboratory Tests Payment System Proposed Rule. The lawmakers expressed their concern that laboratories will not be able to comply with
the proposed rule’s implementation timeline, and asked that it be delayed.
A number of laboratories are prohibited from participating in the reporting process, which the members of Congress believe will skew the market data and
result in Medicare rates that are not reflective of true market prices. They suggest that CMS use a more inclusive method of determining which laboratories
should report data and allow any laboratory to voluntarily report. They also ask that CMS delay implementation of the reporting timeline, because it gives
little time to prepare, certify and submit data points.
Also, the Protecting Access to Medicare Act of 2014 (PAMA) creates a new category of tests, Advanced Diagnostic Laboratory Tests (ADLTs) — these are tests
that must analyze multiple biomarkers of DNA, RNA or proteins. However, CMS excludes proteins from the criteria in the proposed rule. The members also
asked that CMS change the ADLT definition to reflect the statute.
To read the letter, click
Senate and House Pass Medicare Changes at Last Minute
A bipartisan group of members was successful in expediting passage of S. 2425 sponsored by Senators Rob Portman (R-OH) and Bob Casey (D-PA). This
legislation includes a blanket hardship exemption from 2015 meaningful use penalties to all providers who apply for it. Doctors would have until March 15
to apply for the exemptions and Hospitals until April 1. The legislation also provides for a one-year delay in applying Medicare competitive bid pricing to
complex rehab accessories.
An attempt was made to pass legislation to grandfather Hospital Outpatient Departments in the development stage so they would not be subject to site
neutral payment requirements just enacted. However, that effort did not get enough momentum to be considered before both chambers adjourned.
Senators Ask CMS to Stop Rising Drug Prices
On Dec. 17, a group of Democratic senators wrote to the Centers for Medicare and Medicaid Services (CMS) asking what it can do to stop rising drug prices.
Despite rising interest from lawmakers, there is little indication that Congress has a consensus proposal to prevent higher drug prices. Therefore,
lawmakers are looking to CMS for help. They also asked CMS a number of additional questions: 1) can CMS give the public comparisons of drugs based on price
and effectiveness; 2) how does CMS plan to ensure that exchange plans offer sufficient drug coverage; 3) how does CMS plan to use its authority to examine
the potential of alternative payment mechanisms; 4) how can CMS use comparative effectiveness research to improve beneficiary outcomes and lower program
spending; and 5) how is CMS dealing with Medicaid managed care plans? The lawmakers also want CMS to advertise its website for comparing drug coverage and
cost sharing in individual plans.
Sen. Ben Sasse Lifts Hold on HHS Nominees After Receiving Information from HHS
Sen. Ben Sasse (R-NE) recently lifted his hold on the pending nominees in the U.S. Department of Health and Human Services (HHS). This list includes Andy
Slavitt for Director of the Centers for Medicare and Medicaid Services (CMS) and Robert Califf for commissioner of the U.S. Food and Drug Administration
(FDA). Sasse lifted the hold after HHS gave his office the information he requested regarding the Affordable Care Act’s (ACA) CO-OP program. There has been
discussion of holding a vote on Califf’s nomination early next year.
Discharge Planning Proposed Rule Focuses on Patient Preferences
On Dec. 14, the Centers for Medicare and Medicaid Services (CMS) released a proposed rule to revise the discharge planning requirements
that hospitals, including long-term care hospitals and inpatient rehabilitation facilities, critical access hospitals and home health agencies, must meet
in order to participate in the Medicare and Medicaid programs. The proposed changes would tweak the discharge planning requirements by: bringing them into
closer alignment with current practice; trying to improve patient quality of care and outcomes; and reducing avoidable complications, adverse events and
The proposed rule would also implement the discharge planning requirements of the Improving Medicare Post-Acute Care Transformation Act of 2014 (IMPACT
Act), which aims to improve consumer transparency and beneficiary experience during the discharge planning process. The IMPACT Act requires hospitals,
critical access hospitals and certain post-acute care providers to use data on both quality and resource use measures to assist patients during the
discharge planning process, while taking into account the patient’s goals of care and treatment preferences.
Under the proposed rule, hospitals and critical access hospitals would be required to develop a discharge plan within 24 hours of admission or registration
and complete a discharge plan before the patient is discharged home or transferred to another facility. This would apply to all inpatients and certain
types of outpatients, including patients receiving observation services, patients who are undergoing surgery or other same-day procedures where anesthesia
or moderate sedation is used and emergency department patients who have been identified by a practitioner as needing a discharge plan.
Also, hospitals, critical access hospitals and home health agencies would be required to:
Provide discharge instructions to patients who are discharged home (proposed for hospitals and critical access hospitals only);
Have a medication reconciliation process with the goal of improving patient safety by enhancing medication management (proposed for hospitals and
critical access hospitals only);
For patients who are transferred to another facility, send specific medical information to the receiving facility; and
Establish a post-discharge follow-up process (proposed for hospitals and critical access hospitals only).
Comments on the proposed rule must be received no later than 5 p.m. on Jan. 4, 2016.
For more information, click
Center for Health Care Strategies Says Additional Measures Needed to Test Duals Demos
The Centers for Medicare and Medicaid Services (CMS) is currently developing a star-rating system for Medicare-Medicaid plans participating in the duals
demonstrations. However, the non-profit Center for Health Care Strategies (CHCS) says that more quality measures on care coordination and care management
are necessary to measure the performance of both the demos and the integrated special needs plans. CHCS says that Medicare-Medicaid enrollees are beginning
to benefit from integrated care, but that current measures may not fully capture how the programs are improving individual lives.
CMS says that the star-ratings system will include measures to allow the comparison of the duals demonstrations’ performance to other such plans, Medicare
Advantage-Prescription Drug plans and fee-for-service Medicare. The rating system will address 1) community integration and long-term services and support;
2) the management of chronic conditions and health outcomes; 3) prevention; 4) member experience with plans and providers; and 5) plan performance on
administrative duties. Comments are due for the Medicare-Medicaid plans’ star-ratings system by Dec. 21.
IRS Publishes Guidance Restating Employer Reporting Penalty Relief
On Dec. 17, the Internal Revenue Service (IRS)
published guidance saying that it will not punish employers who do not file correct forms
reporting on health benefits to employees — so long as they make a good faith effort to collect that information. The guidance is intended to give more
time to develop appropriate procedures for collecting data and compliance with new reporting requirements. When penalties are enforced, employers would be
fined up to $250 per form or a maximum of $3 million for having false or missing data. The guidance clarifies previous IRS proposals, including one that
employers with 50 or more workers have to provide coverage that meets certain benefits, or pay a fine. The new fine for 2016 is $2,160 per employee for no
coverage offered, and $3,240 if coverage is offered that doesn’t meet minimum requirements. IRS seeks comments on this and other provisions by Feb. 18,
3. State Activities
Michigan: CMS Announces Approval of Michigan 1115 Waiver
On Dec. 17, the Centers for Medicare and Medicaid Services (CMS)
announced its approval of a
needs to extend its Medicaid demonstration — without the wavier, the demonstration would have ended in April 2016. The waiver incorporates some
conservative concepts, including a requirement that Medicaid enrollees earning above the poverty line must choose after four years of coverage to either
enroll on healthcare.gov or stay in Medicaid and pay up to 7 percent of household income toward health care costs. This is higher than the 5 percent
ceiling that CMS gives to other states.
A list of special terms and conditions can be found
Iowa: Transition to Medicaid Managed Care Cannot Start Yet
The Centers for Medicare and Medicaid Services (CMS) told Iowa on Dec. 18, that the state cannot begin implementing a transition to Medicaid managed care
at the start of 2016. Iowa has been pushing for that start date. Instead, CMS believes the state will be ready March 1.
CMS has told Iowa that there are gaps in the state’s readiness to implement a statewide managed care program, including CMS’s belief that the managed care
plans’ provider networks were not fully developed.
4. Regulations Open for Comment
Department of Health and Human Services (HHS) Proposes Updates to “the Common Rule”
HHS and 15 other agencies released a notice of proposed rulemaking Sept. 2 for the Common Rule, the
existing regulatory framework to transparency and oversight for scientific research involving human subjects. The proposed changes are to address the
substantial changes that have occurred within scientific research. Current regulations have been in place since 1991 and are followed by 18 federal
agencies. Proposed updates to the rule include:
Strengthened informed consent provisions
Requirements for administrative or IRB review that would align better with the risks of the proposed research
New data security and information protection standards
Requirements for written consent for use of an individual’s biological samples, for example, blood or urine, for research with the option to consent to
their future use for unspecified studies
Requirement, in most cases, to use a single institutional review board for multisite research studies
Application of rule to clinical trials, regardless of funding source, if they are conducted in a US institution that receives funding from a Common
Rule agency for research involving human participants.
In July 2011, HHS issued an Advance Notice of Proposed Rulemaking to seek the public’s input on updating the Common Rule. The proposed rule issued reflects
input and requests comments for HHS to consider as it drafts the final rule. HHS will take public comment on the proposed rule until Jan 6, 2016.
For a press release detailing changes to the rule visit hhs.gov.
Food and Drug Administration (FDA) Issues Final Rule to Phase Out Trans Fats
FDA issued a final rule June 16
that gives the food manufacturers three years to phase out partially hydrogenated oils (PHOs), which are still used in a wide variety of food products from
microwave popcorn to cake frosting. The decision finalizes an agency determination that PHOs, the primary dietary source of artificial trans fat in
processed foods, are not “generally recognized as safe” or GRAS for use in human food. Since 2006, manufacturers have been required to include trans fat
content information on the Nutrition Facts label of foods. Between 2003 and 2012, the FDA estimates that consumer trans fat consumption decreased about 78
percent and that the labeling rule and industry reformulation of foods were key factors in informing healthier consumer choices and reducing trans fat in
foods. Comments on the final rule are due by June 18, 2018.
More information on FDA’s decision can be found in the agency’s press release.
CMS Releases Proposed Rule with New Discharge Planning Requirements
The Centers for Medicare and Medicaid Services (CMS) released a proposed rule that would require all hospitals develop a
written discharge plan for all inpatient and many outpatients in an attempt to reduce readmissions. The proposed rule, “Medicare and Medicaid Programs;
Revisions to Requirements for Discharge Planning for Hospitals, Critical Access Hospitals, and Home Health Agencies,” would require hospitals to develop a
discharge plan based on the needs of each applicable patient within 24 hours of admission. The plan would include a medication reconciliation process.
Hospitals would be required to establish a process for patients who are transferred to a different facility or who went home.
CMS noted that the requirements could help reduce readmissions by a third. Until now, hospitals have had the ability to decide which patients need a
written discharge plan, and have increasingly used the plans to reduce readmission and avoid the Affordable Care Act’s (ACA) financial penalties. Comments
will be accepted until no later than 5 p.m. on Jan. 4, 2016.
A press release can be found here.
CMS Issues Final Rule to Ensure Medicaid Services for Beneficiaries and Issues Request for Information on the Rule
On Oct. 29, the Centers for Medicare and Medicaid Services (CMS) issued a final rule that ensures Medicaid beneficiaries have sufficient
access to covered Medicaid services. CMS said that the rule, entitled “Methods for Assuring Access to Covered Medicaid Services,” will allow states and CMS
to make more informed decisions when considering whether proposed changes to Medicaid fee-for-service payment rates are sufficient to ensure the
beneficiaries’ access to those services. States will have to create access review plans that outline how states will ensure access to health care services
and to examine how cuts to provider payments will affect the care received.
The rule strengthens CMS’s oversight of Medicaid reimbursement and beneficiary access to providers. It will go into effect in January and CMS issued a Request for Information (RFI) to get feedback on how to make
sure access requirements are being met. Comments will be accepted until no later than 5 p.m. on Jan. 4, 2016.
EEOC Issues Proposed Rule Amending the Genetic Information Nondiscrimination Act (GINA)
On Oct. 30, the U.S. Equal Employment Opportunity Commission (EEOC) issued a proposed rule clarifying
when, under the Genetic Information Nondiscrimination Act (GINA), employers who offer wellness programs as part of group health plans can provide
incentives to an employee’s spouse to provide information about his or her current or past health status. (This is different from the April EEOC
related to the Americans with Disabilities Act.) The proposed rule clarifies that an employer can offer limited incentives in exchange for the employee’s
spouse providing information about his or her current or past health status. EEOC will accept comments on the new proposed rule through Dec. 29, 2015.
A press release on the proposed rule can be found here.
CMS Soliciting Comments on Episode Groups as Required by MACRA
The Centers for Medicare and Medicaid Services (CMS) is soliciting
on episode groups and on specific clinical criteria and patient characteristics to classify patients into care episode and patient condition groups as
required by Section 101(f) of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), enacted April
16, 2015. The purpose of this commentary is to provide background and context to solicit stakeholder input on the episode groups that CMS has developed
pursuant to Section 3003 of the Affordable Care Act (ACA). CMS is also seeking stakeholder input on the future role of episode groups in resource use
Comments should be sent to by 11:59 p.m. EST on Feb. 15, 2016.
FDA Seeks Comments on Whether It Should Define “Natural” and If So, How?
Because of a series of competing citizen petitions, GMO labeling issues and congressional concern, the US Food and Drug Administration (FDA) is seeking
public input on whether it should define the term “natural” for use on food product labels, and, if so, how to do so.
On Nov. 12, FDA published a request for feedback. FDA policy to date has
not restricted the use of the word “natural” on food labeling unless the product has added color, synthetic substances or flavoring.
FDA has received four citizen petitions over the past two years asking the agency to issue regulations on the use of the term, and in July the House of
Representatives passed a proposal on GMOs that would require FDA to define the term “natural” for product labeling.
FDA seeks feedback on the following questions:
What types of foods should be able to use the term?
Should only raw agriculture products be able to use the term?
Should only single-ingredient foods, such as bottled water or bagged spinach, be able to use the term?
If multi-ingredient foods can use the term, what types of ingredients would disqualify a product from using it?
What data or other information shows how consumers associate, confuse or compare the terms “natural” with “organic”?
What data or other information shows how consumers associate, confuse or compare the term “natural” with the term “healthy”?
The comment period is open until Feb. 10, 2016.
HHS Releases Notice of Benefit and Payment Parameters Proposed Rule for Health Insurance Marketplaces for 2017
On Nov. 20, the U.S. Department of Health and Human Services (HHS) released the proposed rule providing the payment parameters that would apply
to the 2017 benefit year and new standards relating to consumers’ experience in the Marketplaces.
The policies included in the proposed rule include payment parameters, Market rules, eligibility, enrollment and benefits.
Highlights of the proposed rule are:
Another recalibration of risk adjustment factors for the 2017 year — the department is proposing to incorporate preventive services into their
simulation of plan liability as part of the recalibration. They are seeking comments on other improvements that could be made to the risk adjustment
A separate, lower default risk adjustment charge for smaller issuers, defined as issuers with 500 or fewer billable member months in a state’s
individual and small group markets combined in a benefit year. HHS believes this proposal would have a minimal impact on risk transfers;
A raise in the default risk adjustment charge from the 75th percentile to the 90th percentile of absolute transfers nationwide as a percent of state
average premium. This adjustment would be designed to prevent the charge from being a low-cost option for issuers;
A federally facilitated Marketplace (FFM) user fee rate of 3.5 percent for 2017 and a fee of 3 percent for those state-based Marketplaces using the
A maximum annual limitation on cost sharing for 2017 of $7,150 for individual coverage and $14,300 cumulatively for family coverage;
Establishment of one or more separate risk pools for each college or university by issuers of student health insurance plans, provided the risk pools
are based on a bonafide school-related classification and on a health status-related factor;
Requirement that all issuers submit the unified rate review template for all single risk pool products regardless of whether they propose rate
increases, decreases or no change in rates for these products;
An enrollment period for the individual market to be Nov. 1, 2016, through Jan. 31, 2017;
Third employer choice models for the federally facilitated SHOP plans included and comments about a fourth option for the 2017 plan year sought. The
third option would give employers the choice to offer all plans on all actuarial levels from one issuer, called a “vertical choice.” The fourth option
would allow employers to select a metal level and employees could choose from plans at that level and one level higher. CMS also seeks comments on
whether FFM states should be able to add additional models to their SHOP programs; and
The role of navigators expanded to include more post-enrollment activities, such as filing appeals, applying for exemptions and assisting in the
transition from coverage to care.
Comments are due at the close of business on Dec. 21, 2015.
For a related press release, click here.
FDA Reopens Comment Period for Tobacco Clarification Rule
The U.S. Food and Drug Administration (FDA) reopened the comment period for the
rule entitled “Clarification of When Products Made or Derived from Tobacco Are Regulated as Drugs or Devices.” The rule describes the circumstances in
which a product made or derived from tobacco that is intended for human consumption will be subject to regulation as a drug, device or a combination
product under the Federal Food, Drug, and Cosmetic Act (the FD&C Act). It is intended to provide direction to regulated industry following recent
FDA is taking this action in response to a request for an extension to allow interested parties additional time to submit comments. Comments must now be
submitted by Dec. 30, 2015.
HHS Posts Guidance for State Innovation Waivers
On Dec. 11, the Department of Health and Human Services (HHS) posted guidance for states interested in seeking a State Innovation Waiver under Section 1332
of the Affordable Care Act (ACA). State Innovation Waivers allow states to receive federal funding to implement alternative models of health care coverage
that provide affordable coverage to their residents. The notice clarifies that the minimum length of public notice and comment periods for waiver
applications is 30 days.
To see the guidance, click
If you have any questions, contact the following individuals at
Kennan, Senior Vice President
Charlie Iovino, Vice
Caroline Perrin, Research Assistant
Founded in 1998, McGuireWoods Consulting LLC
(MWC) is a full-service public affairs firm offering infrastructure and
economic development, strategic communications & grassroots, and government
relations services. McGuireWoods Consulting is a subsidiary of the
law firm and has been named in The National Law Journal's special annual
report, "The Influence 50," for the past several years. In the most recent
report, McGuireWoods Consulting was ranked 15th of the 1,900 government
relations firms in Washington, D.C.
To sign up for the Weekly Washington Healthcare Update, use our online
McGuireWoods Consulting LLC
2001 K Street
Washington, DC 20006-1040